Health Experts Issue Caution Over Unapproved Peptides as FDA Weighs Easing Restrictions The pharmaceutical industry has seen a surge in the development and use of peptides due to their potential benefits in treating various diseases.
These short chains of amino acids have been shown to have therapeutic properties that can be more targeted and efficient than traditional small molecule drugs.
However, this increased interest in peptides has raised concerns among health experts about the safety and efficacy of unapproved peptides being used in clinical settings.